Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 4071-4080 Newer>

The Motley Fool August 29, 2007 Brian Orelli	Inverness Trades Stock for Revenue Inverness Medical Innovations announces plans to buy the biotech company Matritech, bringing to eight the total number of acquisitions Inverness has made in the past year and a half.
The Motley Fool August 29, 2007 Rich Duprey	Medco's Potentially Perilous Purchase Is pharmacy-benefits manager Medco Health Solutions risking its own health by buying diabetes-testing supplier PolyMedica? The deal may end up being so expensive as to drain Medco's own performance.
The Motley Fool August 29, 2007 Brian Lawler	PDL Lands in a Hazard The biopharma announces a dramatic shift following the failure of its lead drug. Shares of PDL are down only 19% this morning, presumably because the thought of a leaner and thriftier PDL with its royalty-generating potential is a welcome relief to some investors.
Inc. September 2007 Cara Cannella	How I Did It: Todd Johnson, President and CEO, Hospital Partners of America Cost pressures may be straining health care providers, but there is money in the hospital business.
The Motley Fool August 28, 2007 Brian Orelli	FDA Makes Cows Happy The FDA approves Omrix's human-derived thrombin, which replaces a version made from cattle.
The Motley Fool August 28, 2007 Brian Orelli	A Combination to Clear Your Head Merck and Schering-Plough get together again. But who can blame them? Their partnerships have been making both companies lots of money. Investors, take note.
The Motley Fool August 28, 2007 Rich Duprey	Candela's Chance to Fan the Flames The maker of lasers used in aesthetic procedures receives FDA approval for an innovative pain reduction technology. Investors, it needs something. Sales have been giving off a pretty weak signal lately, and management admits it has been losing market share.
The Motley Fool August 28, 2007 Brian Orelli	Teva Gets a Two-For Even for a maker of generic drugs, getting two FDA drug approvals in as many business days is a feat not often seen. Teva Pharmaceuticals managed to do it, though. Investors, take note.
The Motley Fool August 28, 2007 Andrew R. Vaino	Cardiome's Hearty Outlook If the FDA renders a favorable decision on an anti-fibrillation drug, Cardiome's heart may well skip a beat. As with any investment based on FDA approval, of course, there is substantial risk involved.
The Motley Fool August 27, 2007 Brian Orelli	Repairing a Broken Heart Stem cells may be the new cure. If research continues on track, Geron expects to ask FDA to start clinical trials late next year or in early 2009. Investors, take note.
<Older 4071-4080 Newer> Return to current articles.